Submitted:
23 September 2026
Posted:
24 September 2026
You are already at the latest version
Abstract
The main objective of the present study was to investigate the application of solvents and nanoparticles as pharmaceutical nanocarriers in the pharmaceutical industry. This descriptive study was conducted in June 2021 based on relevant sources and scientific articles. The study focused on the applications of solvents in nanopharmaceuticals and aimed to elucidate their role and relevance in this field. Based on the findings of the reviewed literature, the use of nanocarriers can enhance drug efficacy and improve the uniformity of nanoparticles in terms of size and structural characteristics. Nanotechnology enables targeted drug delivery and allows control over the timing, location, and rate of drug release. The functionalization or conjugation of nanopolymers may reduce drug toxicity, while hydrolysis-based mechanisms can contribute to drug release. Nanopharmaceutical systems involving biomolecules such as lysozyme may exhibit dipolar characteristics and liquid-crystalline behavior, resulting in properties associated with both liquid and solid states. Overall, the application of nanopharmaceutical technologies can improve the quality of pharmaceutical products and enhance the efficiency of drug production. Further research is recommended to investigate the potential applications of nanopharmaceuticals in the prevention and treatment of COVID-19.
Keywords:
pharmaceutical nanocarriers
; nanocarrier applications
; pharmaceutical solvents
; deep eutectic solvents (DES)
Introduction
In recent decades, nanotechnology has emerged as a rapidly developing field with applications across a wide range of scientific and technological disciplines. The pharmaceutical industry has also benefited substantially from advances in nanotechnology, leading to the development of innovative drug-delivery systems and the introduction of novel pharmaceutical products [1]. Over the past decade, the application of drug-loaded nanocarriers in vivo has received considerable attention as a strategy for improving the therapeutic efficacy of various drugs, particularly anticancer agents. Numerous nanoparticle-based systems have been developed for drug delivery and targeted therapy, while many others remain under active investigation. The use of drug-loaded nanocarriers is primarily intended to protect therapeutic agents from degradation, reduce undesirable side effects, and improve drug availability and accumulation at the target site [2].
Nanoparticles have attracted considerable interest because of their broad applications in biological, pharmaceutical, and medical sciences. They can serve as carriers for a wide variety of therapeutic and biological agents, including small hydrophilic and hydrophobic drugs, vaccines, proteins, and other bioactive molecules. One of the principal objectives of drug-delivery systems is to achieve an appropriate concentration of a therapeutic agent at a specific tissue or organ and at a desired time, thereby improving therapeutic efficacy while minimizing systemic adverse effects [3]. The rapid development of nanotechnology has also promoted interdisciplinary research and facilitated the integration of materials science, chemistry, biology, pharmacology, and medicine in the development of advanced drug-delivery systems.
Nanoparticles are generally defined as particulate systems with dimensions in the nanometer range, commonly between approximately 1 and 100 nm. In recent years, they have attracted substantial attention as potential platforms for drug-delivery applications. Nanocarrier-based pharmaceutical systems have consequently become an important area of research and development, with increasing applications in pharmaceutical and biomedical fields. In this context, Baft-o-Gene Pasargad Company has conducted research and development activities aimed at advancing domestic capabilities in pharmaceutical and biomedical technologies. Its research activities have included several areas of medicine and biomedical science, including cancer, stroke, Parkinson’s disease, and Alzheimer’s disease, with particular emphasis on improving drug efficacy and reducing adverse effects [4].
A wide range of materials, including natural and synthetic polymers, metals, lipids, and other biomaterials, can be employed in the fabrication of nanoparticles. Depending on the composition and preparation method, nanoparticles can exhibit different sizes, morphologies, surface properties, and physicochemical characteristics. In recent years, increasing attention has been directed toward advanced drug-delivery systems, including nanomedicines, for the treatment of various diseases. The development of such systems requires suitable carriers and formulations capable of delivering an appropriate dose of a therapeutic agent to the target site while minimizing adverse effects. In this regard, colloidal carriers such as liposomes and polymeric nanoparticles have emerged as important platforms for drug delivery. Nanoparticle-based delivery systems can potentially enhance therapeutic efficacy, reduce systemic toxicity, improve drug accumulation at the target site, and provide greater control over drug release.
Macromolecular materials, including both natural and synthetic polymers, are widely used in the preparation of polymeric nanoparticles. Depending on their structural characteristics and preparation methods, polymeric nanoparticles are commonly classified into nanospheres and nanocapsules. Nanospheres have a matrix-type structure in which the drug may be dispersed throughout the polymeric matrix or adsorbed onto its surface [5]. Several approaches based on in situ polymerization have been developed for the preparation of polymeric nanospheres. The appropriate method depends, among other factors, on the solubility of the monomer and the physicochemical characteristics of the polymerization system. In emulsion polymerization, for example, the monomer is dispersed in an immiscible phase, whereas in dispersion polymerization, the monomer is dissolved in a continuous phase that acts as a nonsolvent for the polymer being formed, resulting in polymer precipitation and particle formation. Depending on the specific formulation, surfactants or stabilizers may be employed to improve particle stability. A variety of preparation techniques are available for nanoparticle fabrication, enabling control over particle size, morphology, composition, and other physicochemical properties. The selection of an appropriate preparation method depends on several factors, including the nature of the polymer and drug, drug solubility and biological activity, and the desired particle-size distribution.
Magnetic nanoparticles have also attracted considerable attention because of their potential applications in biomedicine and drug delivery. Magnetite (Fe3O4), an iron oxide with an inverse spinel crystal structure, is one of the most extensively investigated magnetic nanomaterials. In magnetite, Fe3+ and Fe2+ ions occupy specific tetrahedral and octahedral sites within the crystal lattice. Magnetite exhibits ferrimagnetic behavior at room temperature and possesses physicochemical properties that make it attractive for biomedical applications. Its relatively high stability and biocompatibility have contributed to the extensive investigation of magnetite-based colloidal systems for applications such as targeted drug delivery, magnetic separation, imaging, and other biomedical technologies [6].
Nanofiber technology represents another important area of nanomaterial research with potential applications in pharmaceutical and biomedical engineering. Nanofibers possess a high specific surface area and a high surface-area-to-volume ratio, characteristics that make them attractive for drug delivery and tissue-engineering applications. Biodegradable polymeric nanofibers can be fabricated using techniques such as electrospinning, producing fibrous scaffolds with interconnected structures and favorable mechanical and physicochemical properties. These scaffolds can be designed for the incorporation and controlled delivery of a wide range of therapeutic and biological agents, including antibiotics, anticancer drugs, proteins, DNA, and RNA. Owing to their distinctive structural and functional characteristics, polymeric nanofibers have potential applications in both systemic and topical drug delivery. The incorporation of magnetic nanoparticles can further provide magnetic responsiveness and additional functionality to these nanofibrous systems [7].
A solvent is generally defined as a substance capable of dissolving another substance, referred to as the solute, to form a solution. Solvents have numerous applications in pharmaceutical and chemical processes, including the adjustment of viscosity and other physicochemical properties, extraction, purification, and the synthesis and formulation of active pharmaceutical ingredients and other pharmaceutical components. Organic solvents, in particular, are commonly used at different stages of pharmaceutical manufacturing. Following production, residual solvents must be controlled and, where necessary, removed from the final pharmaceutical product in accordance with applicable quality and safety requirements. However, complete removal of residual solvents may not always be technically achievable; therefore, their concentrations must be controlled within established permissible limits.
Organic solvents constitute an important group of solvents used in pharmaceutical manufacturing. Examples include alcohols, esters, acetone, aromatic hydrocarbons such as benzene, toluene, and xylene, as well as chlorinated solvents such as chloroform. From a pharmaceutical safety perspective, residual solvents are commonly classified according to their potential toxicity and the extent to which their presence should be controlled in pharmaceutical products. These categories include Class 1, Class 2, and Class 3 solvents, while some solvent types with insufficient toxicological information may be considered separately.
Class 1 solvents are generally regarded as solvents that should be avoided because of their unacceptable toxicity or environmental hazards. They should not normally be used in pharmaceutical manufacturing unless their use is technically unavoidable and no suitable alternative is available.
Class 2 solvents are solvents that should be limited because of their inherent toxicity. Their residual concentrations in pharmaceutical products must be controlled according to established permissible exposure limits. Wherever technically feasible, manufacturers should minimize their use and ensure that residual concentrations do not exceed the applicable limits.
Class 3 solvents have relatively low toxicological potential and are generally considered acceptable when used under appropriate manufacturing conditions. Their residual levels are controlled according to established requirements, and they are commonly used in pharmaceutical manufacturing processes, including extraction, purification, and washing operations.
For solvents for which adequate toxicological information is unavailable, additional evaluation may be required before their use in pharmaceutical manufacturing can be justified. In such cases, appropriate scientific evidence concerning their safety and acceptable residual levels should be provided to the relevant regulatory authorities.
Nanoparticles are widely investigated as drug-delivery platforms because their physicochemical characteristics can be tailored to improve drug loading, protection, transport, and release. In recent years, considerable attention has also been directed toward the use of different solvent systems in the preparation and modification of nanostructured drug-delivery systems. Appropriate solvent selection can influence nanoparticle formation, particle size, morphology, drug encapsulation, and release behavior. Some nanostructured systems can facilitate the transport of therapeutic agents across biological barriers and provide controlled or sustained drug release, thereby improving drug stability and therapeutic performance.
Deep Eutectic Solvents (DES) have recently attracted increasing interest as alternative solvent systems because of their tunable physicochemical properties and potential applications in pharmaceutical and biomedical technologies. Depending on their composition, DES can be incorporated into or used during the preparation of various drug-delivery systems. Their physicochemical characteristics may influence drug solubility, formulation stability, drug loading, and release behavior. DES have therefore been investigated in association with several nanocarrier platforms, including liposomes, polymeric nanoparticles, and polymeric micelles.
Liposomes are spherical vesicular systems consisting of an aqueous core surrounded by one or more phospholipid bilayers. They can be prepared from natural or synthetic phospholipids and are widely investigated as carriers for both hydrophilic and hydrophobic therapeutic agents. The physicochemical properties of liposomes can be modified through changes in lipid composition, surface characteristics, and formulation conditions. The incorporation or use of appropriate solvent systems may influence liposome formation, stability, drug encapsulation, and release characteristics. In addition, surface modification with polyethylene glycol (PEG) can increase the circulation time of liposomal formulations and reduce their recognition and clearance by the mononuclear phagocyte system. Such approaches have been investigated for the delivery of therapeutic agents, including doxorubicin [8].
Polymeric nanoparticles are among the most extensively investigated nanocarriers for drug delivery because of their relatively high stability, versatility, and potential for large-scale production. DES have also been investigated as components or processing media in polymeric nanoparticle formulations because of their tunable properties and potential to improve the solubility of poorly water-soluble compounds. Depending on their composition and application, DES may influence polymer formation, nanoparticle morphology, drug loading, and drug-release behavior. Polymeric micelles are another important class of nanocarriers. They are generally formed by the self-assembly of amphiphilic block copolymers in aqueous media, producing a hydrophobic core capable of solubilizing poorly water-soluble drugs and a hydrophilic outer shell that contributes to colloidal stability. Surface modification of polymeric micelles can further improve their stability and facilitate targeted drug delivery.
A variety of nanostructures, including liposomes, polymeric nanoparticles, dendrimers, silicon- and carbon-based nanomaterials, and magnetic nanoparticles, have been investigated as carriers for targeted drug-delivery systems. These nanocarriers can interact with therapeutic agents through different physical and chemical mechanisms, thereby influencing drug loading, transport, release, and cellular uptake. Among these systems, magnetic nanoparticles have received particular attention because their response to an external magnetic field offers the possibility of spatially controlled drug delivery [9].
Various pharmaceutical nanocarriers have been investigated for therapeutic applications and drug delivery. Important examples include metallic nanoparticles, magnetic nanoparticles, liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles. In addition to their general applications in drug delivery, nanoparticles have been investigated as potential systems for transporting therapeutic agents across the blood-brain barrier. The blood-brain barrier represents a major physiological obstacle to the delivery of many therapeutic compounds to the central nervous system. Consequently, nanoparticle-based strategies have been proposed to improve drug transport to the brain and enhance the therapeutic potential of drugs targeting neurological disorders [10].
Porous silica nanoparticles have also been investigated as drug-delivery platforms, particularly for cancer therapy. Their high surface area, tunable pore structure, and relatively high drug-loading capacity make them attractive candidates for the encapsulation and controlled release of therapeutic agents. These properties have contributed to increasing interest in porous silica nanoparticles for targeted drug delivery to cancer cells [11].
Drug delivery is one of the major and technically complex areas of pharmaceutical science. Advances in nanotechnology and related disciplines have contributed substantially to the development of more sophisticated drug-delivery mechanisms and systems. Different targeting strategies have been investigated, including physical, passive, and active targeting. Physical targeting can involve external stimuli such as magnetic fields, light, or ultrasound to influence the localization or release of therapeutic agents. Passive targeting may exploit physiological and pathological characteristics of tissues, such as the enhanced permeability and retention effect observed in certain tumors. In contrast, active targeting involves the functionalization of nanocarrier surfaces with specific ligands or recognition molecules designed to interact with receptors or other molecular targets expressed by particular cells or tissues.
Several nanocarrier systems have been developed for these purposes, including nanoliposomes, lipid nanoparticles, solid lipid nanoparticles, and dendrimers. In addition, prodrugs and cellular carriers have been investigated as alternative approaches for improving drug delivery and therapeutic selectivity. Continued advances in these technologies may provide new opportunities for improving the efficacy, safety, and specificity of pharmaceutical treatments [12].
Natural bioactive compounds have also attracted increasing attention in pharmaceutical research. Lavender essential oil, for example, has been reported to possess several biological activities, including antioxidant, antibacterial, anticancer, and anti-inflammatory properties. However, the pharmaceutical application of essential oils may be limited by factors such as poor aqueous solubility, chemical instability, and volatility. Nanoliposomal formulations can potentially overcome some of these limitations by improving the solubility, stability, and delivery of bioactive compounds under in vitro and physiological conditions. Accordingly, liposomal nanosystems loaded with lavender essential oil have been investigated as potential nanocarriers for improving the delivery and therapeutic performance of this bioactive compound. Such studies have reported the potential of liposomal nanocarriers for delivering lavender essential oil to cancer-related targets; however, further investigations, particularly regarding cytotoxicity and safety in human cancer and normal cell lines, are required [8].
Research Methodology
The primary objective of this study was to investigate the applications of solvents and nanoparticles in pharmaceutical nanotechnology, with particular emphasis on their roles in nanopharmaceutical formulations and drug-delivery systems. The study employed a descriptive literature-review approach based on relevant scientific articles, research studies, and available literature on the subject. The review focused on the applications of pharmaceutical solvents in nanomedicine, as well as the role of nanomaterials and nanocarriers in improving drug delivery, controlling drug release, and enhancing the physicochemical properties of pharmaceutical formulations. The collected information was analyzed descriptively to provide an overview of the current applications and potential advantages of these technologies in the pharmaceutical industry.
Results and Discussion
The reviewed literature indicates that nanopharmaceutical technologies have contributed to the development of advanced pharmaceutical formulations with improved drug-delivery performance and greater control over drug release. Various fabrication techniques, including dispersion polymerization, have been investigated for the preparation of polymeric nanoparticles and other nanoscale drug-delivery systems. These approaches can contribute to controlling particle size and morphology and, consequently, to improving the reproducibility and physicochemical characteristics of pharmaceutical formulations.
Nanotechnology also provides opportunities for targeted drug delivery, enabling greater control over the localization, timing, and rate of drug release. The surface functionalization or modification of nanocarriers can further influence their physicochemical properties, biological interactions, cellular uptake, and toxicity profiles. In addition, hydrolysis-sensitive materials and linkages can be incorporated into nanocarrier systems to facilitate controlled or pH-responsive drug release under specific physiological conditions.
The findings further indicate that different classes of nanocarriers, including polymeric nanoparticles, liposomes, micelles, and other nanoscale systems, can be designed to improve drug solubility, stability, bioavailability, and delivery to specific biological sites. The physicochemical properties of the carrier, including particle size, surface characteristics, composition, and drug-loading capacity, play important roles in determining the performance of these systems. Accordingly, the appropriate selection of solvents, nanomaterials, and formulation strategies is an important factor in the development of effective nanopharmaceutical products.
Conclusions
The findings of this descriptive literature review demonstrate that advances in nanotechnology have expanded the range of strategies available for pharmaceutical formulation and drug delivery. Nanocarrier-based systems can provide improved control over particle size, surface characteristics, drug loading, and release behavior, thereby offering opportunities to enhance the performance of conventional pharmaceutical formulations.
Nanotechnology also facilitates targeted and controlled drug delivery by enabling the regulation of the localization, timing, and rate of drug release. Surface modification and functionalization of nanocarriers may further improve their interactions with biological systems and can influence cellular uptake, stability, and toxicity. In addition, the appropriate selection of solvents and solvent-based formulation strategies is important for controlling the physicochemical properties and performance of nanopharmaceutical systems.
Overall, the reviewed evidence suggests that the integration of nanotechnology, suitable pharmaceutical solvents, and advanced nanocarrier systems can contribute to improving the quality and functional performance of pharmaceutical formulations. Future studies should focus on the systematic evaluation of the safety, stability, scalability, and clinical applicability of nanopharmaceutical systems, including their potential applications in the prevention and treatment of emerging infectious diseases such as COVID-19.
References
- Fereshteh, Z.; Niasari, Z.; Salavati, M. A review of precipitation methods for the preparation of nanomaterials. In Special Office for the Development of Nanotechnology; 2018. [Google Scholar]
- Rezaei, M.; Parsafar, M. Application of nanocarriers in drug delivery and cancer treatment. 4th International Conference on Science, Research and Technology, 2016. [Google Scholar]
- Pandey, R.; Khuller, G. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J. Antimicrob. Chemother. 2006, 57(6), 1146–1152. [Google Scholar] [CrossRef] [PubMed]
- Acharya, S.; Dilnawaz, F.; Sahoo, S. K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30(29), 5737–5750. [Google Scholar] [CrossRef] [PubMed]
- Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Préat, V. PLGA-based nanoparticles: An overview of biomedical applications. J. Control. Release 2012, 161(2), 505–522. [Google Scholar] [CrossRef] [PubMed]
- Omrani, M. M.; Kiaie, N.; Ansari, M.; Kordestani, S. S. Enhanced protein adsorption, cell attachment, and neural differentiation with the help of amine-functionalized polycaprolactone scaffolds. J. Macromol. Sci. Part B 2016, 55(6), 617–626. [Google Scholar] [CrossRef]
- Shekunov, B. Y.; York, P. Crystallization process in pharmaceutical technology and drug delivery design. J. Cryst. Growth 2000, 211, 122–136. [Google Scholar] [CrossRef]
- Mukesh, C.; Mondal, D.; Sharma, M.; et al. Choline chloride–thiourea, a deep eutectic solvent: The production of chitin nanofibers. Carbohydr. Polym. 2014, 103, 466–471. [Google Scholar] [CrossRef] [PubMed]
- Gala, U.; Chuong, M. C.; Varanasi, R.; et al. Characterization and comparison of lidocaine–tetracaine and lidocaine–camphor eutectic mixtures based on their crystallization and hydrogen-bonding abilities. AAPS PharmSciTech 2015, 16, 528–536. [Google Scholar] [CrossRef] [PubMed]
- Afjeh Dana, E.; Marivani, M.; Mehrovi, B.; Karimzadeh, F.; Ashtari, K. Development of nanoparticles for drug delivery to the brain, 5th ed.; 2018. [Google Scholar]
- Carter, K. A.; Shao, S.; Hoopes, M. I.; Luo, D.; Ahsan, B.; Grigoryants, V. M.; Pandey, R. K. Porphyrin–phospholipid liposomes permeabilized by near-infrared light. Nat. Commun. 2014, 5, 3546. [Google Scholar] [CrossRef] [PubMed]
- Shi, J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in drug delivery and tissue engineering. Nano Lett. 2010, 10(9), 3223–3230. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.